UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2013
OR
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _______ to _______
Commission file number: 001-35610
ATOSSA GENETICS INC.
(Exact name of registrant as specified in its charter)
Delaware | 26-4753208 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) | |
1616 Eastlake Ave. East, Suite 510 | 98102 | |
Seattle, WA | (Zip Code) | |
(Address of principal executive offices) |
Registrant’s telephone number, including area code: (206) 325-6086
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
þ No ¨Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
þ No ¨Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨ | Accelerated filer ¨ | Non-accelerated filer ¨ | Smaller reporting company þ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
¨ No þThe number of shares of the registrant’s common stock, $0.001 par value per share, outstanding at November 8, 2013May 7, 2014 was 18,024,824.24,428,568.
ATOSSA GENETICS INC.
FORM 10-Q
QUARTERLY REPORT
INDEX
ATOSSA GENETICS INC.
(A DEVELOPMENT STAGE COMPANY)
September 30, | December 31, | ||||||
2013 | 2012 | ||||||
(Unaudited) | (Audited) | ||||||
Assets | |||||||
Current Assets | |||||||
Cash and cash equivalents | $ | 7,693,561 | $ | 1,725,197 | |||
Accounts receivable, net | 299,338 | 141,665 | |||||
Prepaid expense | 559,386 | 122,633 | |||||
Retainers (deposits) | 43,160 | - | |||||
Total Current Assets | 8,595,445 | 1,989,495 | |||||
Fixed Assets | |||||||
Furniture and equipment, net | 443,272 | 159,967 | |||||
Total Fixed Assets | 443,272 | 159,967 | |||||
Other Assets | |||||||
Security deposit | 36,446 | 36,447 | |||||
Intangible assets, net | 4,407,058 | 4,640,224 | |||||
Total Other Assets | 4,443,504 | 4,676,671 | |||||
Total Assets | $ | 13,482,221 | $ | 6,826,133 | |||
Liabilities and Stockholders' Equity | |||||||
Current Liabilities | |||||||
Accounts payable | $ | 31,131 | $ | 68,217 | |||
Accrued expenses | 1,069,759 | 1,374,385 | |||||
Deferred rent | 60,753 | - | |||||
Payroll liabilities | 357,489 | 207,996 | |||||
Contingent liabilities | 402,840 | - | |||||
Other current liabilities | 20,300 | - | |||||
Total Current Liabilities | 1,942,272 | 1,650,598 | |||||
Stockholders' Equity | |||||||
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding | - | - | |||||
Common stock - $.001 par value; 75,000,000 shares authorized, 17,444,824 and 12,919,367 shares issued and outstanding | 17,445 | 12,919 | |||||
Additional paid-in capital | 29,281,396 | 14,894,522 | |||||
Accumulated deficit | (17,758,892) | (9,731,906) | |||||
Total Stockholders' Equity | 11,539,949 | 5,175,535 | |||||
Total Liabilities and Stockholders' Equity | $ | 13,482,221 | $ | 6,826,133 |
March 31, | December 31, | |||||||
2014 | 2013 | |||||||
(Unaudited) | (Audited) | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 16,590,951 | $ | 6,342,161 | ||||
Accounts receivable, net | 91,416 | 139,072 | ||||||
Prepaid expense | 1,017,766 | 932,588 | ||||||
Total current assets | 17,700,133 | 7,413,821 | ||||||
Fixed assets | ||||||||
Furniture and equipment, net | 129,942 | 163,147 | ||||||
Total fixed assets | 129,942 | 163,147 | ||||||
Other assets | ||||||||
Security deposit | 61,309 | 36,446 | ||||||
Intangible assets, net | 4,491,707 | 4,395,633 | ||||||
Total other assets | 4,553,016 | 4,432,079 | ||||||
Total assets | $ | 22,383,091 | $ | 12,009,047 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | - | $ | 9,634 | ||||
Accrued expenses | 744,736 | 637,986 | ||||||
Deferred rent | 35,023 | 48,157 | ||||||
Payroll liabilities | 195,896 | 476,477 | ||||||
Contingent liabilities | 96,201 | 211,493 | ||||||
Other current liabilities | 10,189 | 23,649 | ||||||
Total current liabilities | 1,082,045 | 1,407,396 | ||||||
Stockholders' Equity | ||||||||
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding | - | - | ||||||
Common stock - $.001 par value; 75,000,000 shares authorized, 24,428,568 and 18,574,334 shares issued and outstanding | 24,429 | 18,574 | ||||||
Additional paid-in capital | 44,204,762 | 31,099,691 | ||||||
Accumulated deficit | (22,928,145 | ) | (20,516,614 | ) | ||||
Total stockholders' equity | 21,301,046 | 10,601,651 | ||||||
Total liabilities and stockholders' equity | $ | 22,383,091 | $ | 12,009,047 |
The accompanying notes are an integral part of these consolidated financial statements
3 |
ATOSSA GENETICS INC.
(A DEVELOPMENT STAGE COMPANY)
(UNAUDITED)
For the Three Months Ended September 30, | For The Nine Months Ended September 30, | From April 30, 2009 (Inception) Through September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | 2013 | ||||||||||||
Revenue | ||||||||||||||||
Diagnostic testing service | $ | 72,187 | $ | 104,011 | $ | 361,905 | $ | 376,696 | $ | 837,307 | ||||||
Product sales | 4,410 | 1,565 | 223,440 | 6,690 | 231,380 | |||||||||||
Total Revenue | 76,597 | 105,576 | 585,345 | 383,386 | 1,068,687 | |||||||||||
Cost of Revenue | ||||||||||||||||
Diagnostic testing service | 25,938 | 9,000 | 75,893 | 29,985 | 111,638 | |||||||||||
Product sales | - | - | 238,669 | - | 243,833 | |||||||||||
Total Cost of Revenue | 25,938 | 9,000 | 314,562 | 29,985 | 355,471 | |||||||||||
Loss on reduction of inventory to LCM | - | 6,077 | - | 29,884 | 121,910 | |||||||||||
Gross Profit | �� | 50,659 | 90,499 | 270,783 | 323,517 | 591,306 | ||||||||||
Selling expenses | 373,418 | 87,704 | 965,383 | 281,971 | 1,605,259 | |||||||||||
Research and development expenses | 321,111 | 548,108 | 731,258 | 1,508,944 | 4,288,644 | |||||||||||
General and administrative expenses | 2,858,027 | 590,359 | 6,600,819 | 1,896,254 | 12,423,155 | |||||||||||
Total operating expenses | 3,552,556 | 1,226,171 | 8,297,460 | 3,687,169 | 18,317,058 | |||||||||||
Operating Loss | (3,501,897) | (1,135,672) | (8,026,677) | (3,363,652) | (17,725,752) | |||||||||||
Interest income | 53 | 46 | 53 | 1,219 | 6,641 | |||||||||||
Interest expense | 1 | 7,756 | 360 | 11,816 | 39,531 | |||||||||||
Net Loss before Income Taxes | (3,501,845) | (1,143,382) | (8,026,984) | (3,374,249) | (17,758,642) | |||||||||||
Income Taxes | - | - | - | - | 250 | |||||||||||
Net Loss | $ | (3,501,845) | $ | (1,143,382) | $ | (8,026,984) | $ | (3,374,249) | $ | (17,758,892) | ||||||
Loss per common share - basic and diluted | $ | (0.22) | $ | (0.10) | $ | (0.55) | $ | (0.30) | $ | (1.95) | ||||||
Weighted average shares outstanding, basic & diluted | 15,830,033 | 11,256,867 | 14,697,221 | 11,256,867 | 9,127,656 |
For the Three Months Ended March 31 , | From April 30, 2009 (Inception) Through March 31, | |||||||||||
2014 | 2013 | 2014 | ||||||||||
Revenue | ||||||||||||
Diagnostic testing services | $ | 24,124 | $ | 169,230 | $ | 908,644 | ||||||
Product sales | - | 13,440 | 231,380 | |||||||||
Total revenue | 24,124 | 182,670 | 1,140,024 | |||||||||
�� | ||||||||||||
Cost of revenue | ||||||||||||
Diagnostic testing services | - | 47,599 | 141,509 | |||||||||
Product sales | - | 18,865 | 244,919 | |||||||||
Total cost of revenue | - | 66,464 | 386,428 | |||||||||
Loss on obsolete inventory & LCM | - | - | 271,856 | |||||||||
Gross profit | 24,124 | 116,206 | 481,740 | |||||||||
Selling expenses | 237,838 | 272,575 | 2,135,505 | |||||||||
Research and development expenses | 422,503 | 220,192 | 5,084,999 | |||||||||
General and administrative expenses | 1,774,708 | 1,564,872 | 16,155,879 | |||||||||
Total operating expenses | 2,435,049 | 2,057,639 | 23,376,383 | |||||||||
Operating loss | (2,410,925 | ) | (1,941,433 | ) | (22,894,643 | ) | ||||||
Interest income | 143 | - | 7,026 | |||||||||
Interest expense | 749 | 7 | 40,280 | |||||||||
Net loss before income taxes | (2,411,531 | ) | (1,941,440 | ) | (22,927,897 | ) | ||||||
Income taxes | - | - | 248 | |||||||||
Net loss | $ | (2,411,531 | ) | $ | (1,941,440 | ) | $ | (22,928,145 | ) | |||
Loss per common share - basic and diluted | $ | (0.10 | ) | $ | (0.14 | ) | $ | (2.16 | ) | |||
Weighted average shares outstanding, basic & diluted | 24,419,060 | 13,421,119 | 10,604,575 |
The accompanying notes are an integral part of these consolidated financial statements.
ATOSSA GENETICS INC.
(A DEVELOPMENT STAGE COMPANY)
(UNAUDITED)
For the Nine Months Ended September 30, | For The Period From April 30, 2009 (Inception) to | |||||||||
2013 | 2012 | September 30, 2013 | ||||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||||
Net loss | $ | (8,026,984) | $ | (3,374,249) | $ | (17,758,892) | ||||
Common shares issued for services | 144,391 | - | 215,392 | |||||||
Compensation cost for stock options granted | 1,187,717 | 96,251 | 1,479,981 | |||||||
Loss on reduction of inventory to LCM | - | 29,884 | 121,910 | |||||||
Loan initiation fee accrued for notes payable | - | - | 2,000 | |||||||
Depreciation and amortization | 350,536 | 25,586 | 496,711 | |||||||
Contingent loss | 402,840 | - | 402,840 | |||||||
Bad debt expense | 228,841 | - | 228,841 | |||||||
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||||
Increase in accounts receivable | (386,514) | (174,183) | (528,179) | |||||||
Increase in inventory | - | (29,884) | (121,910) | |||||||
Decrease (Increase) in prepaid expenses | 71,439 | (8,791) | (51,194) | |||||||
Increase in security deposits | (43,160) | (30,589) | (79,608) | |||||||
Decrease (Increase) in accounts payable | (37,086) | 7,335 | 31,131 | |||||||
Decrease in accrued payroll | 149,493 | - | 149,493 | |||||||
Increase in deferred rent | 60,753 | - | 60,753 | |||||||
Decrease (Increase) in accrued expenses | (304,626) | 1,491,014 | 1,322,756 | |||||||
Increase in other current liabilities | 20,300 | - | 20,300 | |||||||
Net cash used in operating activities | (6,182,060) | (1,967,626) | (14,007,675) | |||||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||||
Purchase of furniture & fixtures | (346,007) | - | (537,054) | |||||||
Purchase of software | (54,667) | - | (135,133) | |||||||
Net cash used in investing activities | (400,674) | - | (672,187) | |||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||||
Net proceeds from issuance of common stocks and warrants | 12,551,098 | 400,000 | 22,375,423 | |||||||
Repayments of bank line of credit | - | (750,000) | - | |||||||
Proceeds from (repayments of) loans from related parties | - | 75,375 | (2,000) | |||||||
Cash released from commercial line of credit | - | 750,000 | - | |||||||
Net cash provided by financing activities | 12,551,098 | 475,375 | 22,373,423 | |||||||
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS | 5,968,364 | (1,492,251) | 7,693,561 | |||||||
CASH & CASH EQUIVALENTS, BEGINNING BALANCE | 1,725,197 | 1,910,821 | - | |||||||
CASH & CASH EQUIVALENTS, ENDING BALANCE | $ | 7,693,561 | $ | 418,570 | $ | 7,693,561 | ||||
SUPPLEMENTAL DISCLOSURES: | ||||||||||
Interest paid | $ | 359 | $ | 13,892 | $ | 33,067 | ||||
Income taxes paid | $ | - | $ | - | $ | 250 | ||||
NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||||
Common stock and warrants issued for asset purchase | $ | - | $ | 4,674,853 | $ | 4,674,853 | ||||
Options issued for previously accrued director compensation | $ | - | $ | 45,000 | $ | 45,000 | ||||
Commitment shares distributed for capital contribution | $ | 2,387,250 | $ | - | $ | 2,387,250 | ||||
Amortization of commitment shares issued for distributed shares | $ | 1,879,058 | $ | - | $ | 1,879,058 |
For the Three Months Ended March 31, | For The Period From April 30, 2009 (Inception) to March | |||||||||||
2014 | 2013 | 31, 2014 | ||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||||||
Net loss | $ | (2,411,531 | ) | $ | (1,941,440 | ) | $ | (22,928,145 | ) | |||
Common shares issued for services | - | 155,969 | 249,279 | |||||||||
Compensation cost for stock options granted | 230,181 | 274,512 | 1,966,205 | |||||||||
Loss on reduction on obsolete inventory and LCM | - | - | 271,856 | |||||||||
Impairment loss on long-life assets | 158,292 | |||||||||||
Loan initiation fee accrued for notes payable | - | - | 2,000 | |||||||||
Depreciation and amortization | 125,097 | 98,945 | 744,206 | |||||||||
Contingent loss | - | 211,493 | ||||||||||
Bad debt expense | 27,860 | - | 382,721 | |||||||||
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||||||
Decrease (Increase) in accounts receivable | 19,796 | (117,675 | ) | (474,137 | ) | |||||||
Increase in inventory | - | (271,856 | ) | |||||||||
Increase in prepaid expenses | (245,178 | ) | (90,789 | ) | (425,805 | ) | ||||||
Increase in security deposits | (24,863 | ) | - | (61,309 | ) | |||||||
Decrease in accounts payable | (9,634 | ) | (33,626 | ) | - | |||||||
Decrease (Increase) in accrued payroll | (280,581 | ) | 94,371 | 195,896 | ||||||||
Decrease (Increase) in deferred rent | (13,134 | ) | - | 35,023 | ||||||||
Decrease (Increase) in accrued expenses | 106,750 | 279,951 | 789,736 | |||||||||
Decrease in contingent loss liability | (115,292 | ) | - | (115,292 | ) | |||||||
Decrease (Increase) in other current liabilities | (13,460 | ) | (55,030 | ) | 10,189 | |||||||
Net cash used in operating activities | (2,603,989 | ) | (1,334,812 | ) | (19,259,648 | ) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||||||
Purchase of furniture & fixtures | (2,966 | ) | - | (438,455 | ) | |||||||
Purchase of software | (100,000 | ) | (8,500 | ) | (425,839 | ) | ||||||
Net cash used in investing activities | (102,966 | ) | (8,500 | ) | (864,294 | ) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||||||
Net proceeds from issuance of common stock and warrants | 12,955,745 | 1,003,314 | 36,716,893 | |||||||||
Repayments of loans from related parties | - | - | (2,000 | ) | ||||||||
Net cash provided by financing activities | 12, 955,745 | 1,003,314 | 36,714,893 | |||||||||
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS | 10,248,790 | (339,998 | ) | 16,590,951 | ||||||||
CASH & CASH EQUIVALENTS, BEGINNING BALANCE | 6,342,161 | 1,725,197 | - | |||||||||
CASH & CASH EQUIVALENTS, ENDING BALANCE | $ | 16,590,951 | $ | 1,385,199 | $ | 16,590,951 | ||||||
SUPPLEMENTAL DISCLOSURES: | ||||||||||||
Interest paid | $ | 749 | $ | 2,682 | $ | 33,816 | ||||||
Income taxes paid | $ | - | $ | - | $ | 248 | ||||||
NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||||||
Common stock and warrants issued for asset purchase | $ | - | $ | - | $ | 4,674,853 | ||||||
Noncash reclass of prepaid license fees | $ | 15,000 | - | $ | 15,000 | |||||||
Options issued for previously accrued director compensation | $ | - | $ | - | $ | 45,000 | ||||||
Commitment shares distributed for capital contribution | $ | - | $ | 2,387,250 | $ | 3,137,500 | ||||||
Amortization of commitment shares | $ | 75,000 | $ | 79,575 | $ | 2,560,540 |
The accompanying notes are an integral part of these consolidated financial statements.
5 |
ATOSSA GENETICS INC.
(A DEVELOPMENT STAGE COMPANY)
(UNAUDITED)
NOTE 1: NATURE OF OPERATIONS
Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the Mammary Aspirate Specimen Cytology Test System, or MASCT System, which was cleared by the FDA in 2003 asis a medical device that is intended for use in the collectioncollects specimens of nipple aspirate fluid for laboratory cytological testing.(NAF). The Company’s fiscal year ends on December 31st.
In December 2011, the Company established theThe National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory wherewhich performs our NAF cytology test on NAF specimens including those collected with the MASCT System. The current version of the MASCT System, is called the ForeCYTE andBreast Aspirator. The NRLBH is developing other tests such as the ArgusCYTE test, specimens are examined by cytopathology.
In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries) and 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizationsintellectual property rights related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000.$400,000. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The acquired patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.
Development Stage Risk
From April 30, 2009 (inception) through September 30, 2013,March 31, 2014, the Company earned $1,068,687$1,140,024 in revenue from the sale of its productsMASCT Systems and laboratory services. The Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”, which was previously Statement of Financial Accounting Standards No. 7 (“SFAS 7”). Among the disclosures required by ASC 915 are that the Company’s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders’ equity and cash flows disclose activity since the date of the Company’s inception.
Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.
NOTE 2: GOING CONCERN
The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Management’s Plan to Continue as a Going Concern
In order to continue as a going concern, the Company will need among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities, (2) sales of the MASCT System, which is now called the ForeCYTE SystemBreast Aspirator, and laboratory service revenue (once cleared by the FDA and re-launched), and (3) short-term or long-term borrowings from banks, stockholders or other party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.
The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.
NOTE 3: SUMMARY OF ACCOUNTING POLICIES
Basis of Presentation:
The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
Recently Issued Accounting Pronouncements:
The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.
Revenue Recognition:
Overview
The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.
Product Revenue
The Company recognizes revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as the Company has an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. The Company will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, the Company will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.
Service Revenue
The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts willare generally be used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history. The Company estimates it will utilize the
Cost of Revenue:
Cost of revenue consists of cost of diagnostic testing services and cost of product sales. Cost of diagnostic testing services primarily includes direct cost of material, direct labor, equipment, and shipping to process the patient samples (including pathology, quality control analysis, and shipping charges to transport tissue sample) in our laboratory. Costs associated with performing the Company's tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue historywas recognized with respect to determine a proper allowancethat test. Cost of product sales primarily includes manufacturing cost of our MASCT System for doubtful accounts beginning in 2014.
Cash and Cash Equivalents:
Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Use of Estimates:
The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Accounts Receivable:
Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts and bad debt expenses as of September 30, 2013March 31, 2014 and December 31, 20122013 was $228,841$382,721 and $0,$354,861, respectively.
Inventories:
The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Because the sales price of the MASCT System was substantially lower than its cost for the period ended September 30, 2013 and December 31, 2012, resulting in the net realizable value of the MASCT System being determined at zero as of September 30, 2013 and December 31, 2012, through taking the average sales price subtracted by selling expenses per unit. The Company assessed and recorded $0 and $29,884 loss on reduction of inventory to the lower of cost or market for the nine months ended September 30, 2013 and for the year ended December 31, 2012, respectively. Additionally, managementManagement periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. AsDuring the course of September 30,our recall commenced in October 2013, we have recalled a substantial number of MASCT Systems. Based on management’s assessment of those devices and the pending FDA clearance, management decided to establish 100% allowance for valuation reserve on all MASCT Systems, and recorded $149,946 of losses on obsolete inventory for the year ended December 31, 2012,2013. During March 31, 2014, management had identified no additional slow moving or obsolete inventory. The Company outsources product manufacturing to outside manufacturer contactors. The ownership of the goods transfers from the manufacturer to the Company’s customer at the time the products are shipped to the customers. As of September 30,March 31, 2014 and December 31, 2013, there are no inventories on our books.
The Company provides, either directly or through distributors, the ForeCYTE testingNAF specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the NRLBH or other laboratories for diagnostic analysis. These collection kits are considered part of the MASCT System. The Company’s direct sales personnel distributes the kits directly to physicians free of charge, or by offering a rebate to physicians. The Company has not intended to deem the kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits.
Property, plant, and equipment:
Property, plant and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.
Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
Useful Life (in years) | ||||
Machinery and equipment | 5 | |||
Leasehold improvements | 2.083 |
The Company applies the provisions of FASB ASC Topic 360 (ASC 360), “Property, Plant, and Equipment” which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360, at least on an annual basis. ASC 360 requires the impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the three months ended March 31, 2014 and year ended December 31, 2013 $0 and $158,292 was assessed and recorded as impairment on long-life assets.
Intangible assets:
Intangible assets consist of intellectual property and software acquired in the Acueity asset purchase.acquired. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. There was no impairment of intangible assets as of and for the ninethree months ended September 30, 2013March 31, 2014 and the year ended December 31, 2012,2013, respectively.
Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
Useful Life (in years) | ||||
Patents | 9-14 | |||
Capitalized license costs | 10 | |||
Software | 3 |
Research and Development Expenses:
Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.
Share-Based Payments:
In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment”, which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation – Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.
The Company has fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.
NOTE 4: PREPAID EXPENSES
Prepaid expenses consisted of the following:
September 30, 2013 | December 31, 2012 | ||||||
Prepaid stock purchase agreement service fee | $ | 508,442 | $ | - | |||
Prepaid insurance | 27,445 | 62,551 | |||||
Prepaid hardware/software maintenance and support service fee | 23,499 | 20,000 | |||||
Prepaid payroll taxes | - | 40,082 | |||||
$ | 559,386 | $ | 122,633 |
March 31, 2014 | December 31, 2013 | |||||||
Prepaid stock purchase agreement service fee | $ | 576,961 | $ | 651,961 | ||||
Prepaid marketing educational programs | 230,000 | - | ||||||
Prepaid hardware and software | 31,551 | 131,204 | ||||||
Prepaid insurance | 125,714 | 112,517 | ||||||
Retainer and security deposits | 29,540 | 36,906 | ||||||
Other | 24,000 | - | ||||||
$ | 1,017,766 | $ | 932,588 |
NOTE 5: PROPERTY, PLANT, AND EQUIPMENT
Property, plant and equipment consisted of the following:
September 30, 2013 | December 31, 2012 | ||||||
Machinery and equipment | $ | 269,771 | $ | 97,383 | |||
Leasehold improvements | 93,665 | 93,665 | |||||
Capitalized new product development costs | 173,766 | - | |||||
Less: Accumulated depreciation | (93,930) | (31,081) | |||||
Property, plant, and equipment, net | $ | 443,272 | $ | 159,967 |
March 31, 2014 | December 31, 2013 | |||||||
Machinery and equipment | $ | 329,790 | $ | 326,824 | ||||
Leasehold improvements | 93,665 | 93,665 | ||||||
Capitalized new product development costs | - | 15,000 | ||||||
Less: Accumulated depreciation | (135,221 | ) | (114,050 | ) | ||||
Less: Allowance for loss on impairment | (158,292 | ) | (158,292 | ) | ||||
Property, plant, and equipment, net | $ | 129,942 | $ | 163,147 |
Depreciation expense for the ninethree months ended September 30,March 31, 2014 and 2013 was $21,171 and 2012 was $62,849 and $12,970,$4,869, respectively.
NOTE 6: INTANGIBLE ASSETS
Intangible assets consisted of the following:
September 30, | December 31, | ||||||
2013 | 2012 | ||||||
Patents | $ | 4,704,853 | $ | 4,704,853 | |||
Software | 105,133 | 50,466 | |||||
Less: Accumulated amortization | (402,928) | (115,095) | |||||
$ | 4,407,058 | $ | 4,640,224 |
March 31, | December 31, | |||||||
2014 | 2013 | |||||||
Patents | $ | 4,794,853 | $ | 4,794,853 | ||||
Capitalized license costs | 200,000 | - | ||||||
Software | 105,839 | 105,839 | ||||||
Less: Accumulated amortization | (608,985 | ) | (505,059 | ) | ||||
$ | 4,491,707 | $ | 4,395,633 |
Intangible assets amounted to $4,407,058$4,491,707 and $4,640,224$4,395,633 as of September 30, 2013March 31, 2014 and December 31, 2012,2013, respectively, and consisted of patents, capitalized license costs and software acquired. The acquired software mainly consisted of $58,000$58,000 in laboratory software and $31,500$31,500 in the newly developed Company website. The amortization period for the purchased software is 3 years. Amortization expense related to software for the ninethree months ended September 30,March 31, 2014 and 2013 was $8,761 and 2012 was $15,322 and $12,616,$4,678, respectively.
Patents amounted to $4,704,853 and $4,704,853$4,794,853 as of September 30, 2013March 31, 2014 and December 31, 2012,2013, respectively, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction (see Note 13).transaction. Patent assets are amortized based on their determined useful life, and tested annually for impairment. The amortization period was from 9 to 14 years. Amortization expense related to patents was $272,511$93,497 and $0$89,398 for the ninethree months ended September 30,March 31, 2014 and 2013, respectively.
Capitalized license costs consist of fees paid to A5 Genetics KFT, Corporation, pursuant to which the Company received the world-wide (other than the European Union) exclusive license to use the software in the NextCYTE test. Amortization expense related to license costs was $1,668 and 2012,$0 for the three months ended March 31, 2014 and 2013, respectively.
Future estimated amortization expenses as of September 30, 2013March 31, 2014 for the five succeeding years is as follows:
As of December 31, | Amounts | |||
2014 (includes the remainder of the year) | $ | 313,525 | ||
2015 | 412,212 | |||
2016 | 404,951 | |||
2017 | 393,982 | |||
2018 | 393,982 | |||
Thereafter | 2,573,055 | |||
$ | 4,491,707 |
11 |
As of September 30, | Amounts | |||
2014 | $ | 393,073 | ||
2015 | 381,331 | |||
2016 | 378,781 | |||
2017 | 363,902 | |||
2018 | 363,028 | |||
Thereafter | 2,526,943 | |||
$ | 4,407,058 |
NOTE 7: PAYROLL LIABILITIES:
Payroll liabilities consisted of the following:
September 30, 2013 | December 31, 2012 | ||||||
Accrued bonus payable | $ | 297,290 | $ | 189,131 | |||
Accrued payroll liabilities | 40,318 | - | |||||
Accrued payroll tax liabilities | 19,881 | 18,865 | |||||
$ | 357,489 | $ | 207,996 |
March 31, 2014 | December 31, 2013 | |||||||
Accrued bonus payable | $ | 116,031 | $ | 408,362 | ||||
Accrued payroll liabilities | 67,003 | 48,232 | ||||||
Accrued payroll tax liabilities | 12,862 | 19,883 | ||||||
$ | 195,896 | $ | 476,477 |
NOTE 8: STOCKHOLDERS’ EQUITY
The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of Common Stock, par value $0.001$0.001 per share, and 10,000,000 shares of Preferred Stock, par value $0.001$0.001 per share.
Reverse Stock-Split
On September 28, 2010, the Board of Directors approved a 1-for-2.26332 reverse share split for all issued and outstanding shares of Common Stock, with no change to the par value of the Common Stock.
Prior Issuances of Common Stock at Inception
On April 30, 2009 (inception), the Company issued 1,767,316 shares (or 4,000,000 shares prior to the reverse stock-split on September 28, 2010) to Ensisheim Partners LLC, a related party to the Company through common ownership, for cash in the amount of $24,000, or $0.014$0.014 per share (or $0.006$0.006 per share prior to the reverse stock-split on September 28, 2010); 1,325,487 shares (or 3,000,000 shares prior to the reverse stock-split on September 28, 2010) to Manistee Ventures LLC, a related party to the Company through common ownership, for cash in the amount of $18,000, or $0.014$0.014 per share (or $0.006$0.006 per share prior to the reverse stock-split on September 28, 2010); and 883,662 shares (or 2,000,000 shares prior to the reverse stock-split on September 28, 2010) to the Chairman, CEO and President of the Company at that time for cash in the amount of $12,000, or $0.014$0.014 per share (or $0.006$0.006 per share prior to the reverse stock-split on September 28, 2010).
Private Placements and Warrants
On April 28, May 31, June 10, and June 23, 2011, pursuant to Securities Purchase Agreements with various investors (the “Investors”), the Company issued 5,256,800 shares of the Company’s common stock and 5,256,800 warrants (the “Investor Warrants”), each of which entitles the investors to purchase the Company’s common stock exercisable for 1.60at $1.25 per share, for aggregate gross proceeds of $6,571,000$6,571,000 (the “Private Placement”).
Placement Agent Fees
In connection with the Private Placement, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 10%10% of the gross proceeds from sale of the common stocks and warrants, plus a 3%3% non-accountable expense allowance, which resulted in a payment to the Placement Agent of an aggregate of $857,230$857,230 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received 788,520 warrants, each of which entitles the Placement Agent to purchase one share of the Company’s common stock at $1.60$1.60 per share, plus an additional 788,520 warrants (collectively with the warrants exercisable at $1.25$1.25 per share, the “Placement Agent Warrants”), each of which entitles the placement agent to purchase the Company’s common stock at $1.25$1.25 per share. The cash payment of the $857,230 Placement Agent Fee and the $495,876$495,876 aggregated initial fair value of the Placement Agent Warrants (seeFair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.
Warrants
The Warrants, including the Investor Warrants and the Placement Agent Warrants, are exercisable at any time commencing after June 23, 2011 which is the date that the Company completed a “significant private financing” under the terms of the Warrants (the “Initial Exercise Date”). The Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”). The Warrants may be exercised for cash or, at the option of the holder, may be exercised on a cashless basis; however if a registration statement is in effect for the resale of the common stock issuable upon exercise of the Warrants then the Warrants cannot be exercised on a cashless basis. As of September 30, 2013March 31, 2014 such a registration statement was in effect and, therefore, the Warrants cannot be exercised on a cashless basis.
Fair Value Considerations
The Company’s accounting for the issuance of warrantsWarrants to the Investors and the Placement Agent required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrantsWarrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.
The Investor Warrants and the Placement Agent Warrants were initially valued at $1,808,025$1,808,025 or $0.344$0.34 per warrant, $228,712$228,712 or $0.290$0.29 per warrant, and $267,164$267,164 or $0.339$0.34 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the Warrants:
Fair | April-June2011 | December 2011 | ||||||||||
Value Hierarchy Level | Investor Warrants | Placement Agent Warrants | Placement Agent Warrants | |||||||||
Indexed shares | 5,256,800 | 788,520 | 788,520 | |||||||||
Exercise price | $ | 1.60 | $ | 1.60 | $ | 1.25 | ||||||
Significant assumptions: | ||||||||||||
Stock price | 3 | $ | 0.906 | $ | 0.906 | $ | 0.906 | |||||
Remaining term | 3 | 6 years | 6 years | 6 years | ||||||||
Risk free rate | 2 | 2.49 | % | 1.12 | % | 1.12 | % | |||||
Expected volatility | 3 | 53.55 | % | 54.21 | % | 54.21 | % |
Fair | April-June 2011 | December 2011 | ||||||||||||||
Value Hierarchy Level | Investor Warrants | Placement Agent Warrants | Placement Agent Warrants | |||||||||||||
Indexed shares | 5,256,800 | 788,520 | 788,520 | |||||||||||||
Exercise price | $ | 1.60 | $ | 1.60 | $ | 1.25 | ||||||||||
Significant assumptions: | ||||||||||||||||
Stock price | 3 | $ | 0.906 | $ | 0.906 | $ | 0.906 | |||||||||
Remaining term | 3 | 6 years | 6 years | 6 years | ||||||||||||
Risk free rate | 2 | 2.49 | % | 1.12 | % | 1.12 | % | |||||||||
Expected volatility | 3 | 53.55 | % | 54.21 | % | 54.21 | % |
Fair value hierarchy of the above assumptions can be categorized as follows:
(1) | There were no Level 1 inputs. |
(2) | Level 2 inputs include: |
Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
(3) | Level 3 inputs include: |
Stock price- The Company’s common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm’s length transaction.
Remaining term- The Company does not have a history to develop the expected term for its warrants.Warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrantsWarrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
Asset Purchase and Warrants
On September 30, 2012, pursuant to the asset purchase agreement with Acueity, the Company issued 862,500 shares of common stock and 325,000 warrants (“Acueity Warrants”) to the shareholders of Acueity, each of which entitles the recipients to subscribe for and purchase from the Company one share of the Company’s common stock at $5.00$5.00 per share (the “Exercise Price”), subject to a six-month lock up agreement.
Warrants
The Acueity Warrants are exercisable at any time commencing after September 30, 2012 (the “Issuance Date”) and shall expire and no longer be exercisable on the fifth anniversary of the Issuance Date (the “Expiration Date”). The Company may at any time during the term of the Acueity Warrants reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. The Acueity Warrants do not have a cashless exercise provision. There are no redemption features embodied in the Acueity Warrants and they have met the conditions provided in current accounting standards for equity classification.
Fair Value Considerations
The Company’s accounting for the issuance of the Acueity Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.
The Acueity Warrants were valued at $762,353 or $2.3457$2.35 per warrant. The following tables reflect assumptions used to determine the fair value of the Warrants:
Fair Value Hierarchy | September 2012 | |||||||
Level | Acueity Warrants | |||||||
Indexed shares | 325,000 | |||||||
Exercise price | $ | 5.00 | ||||||
Significant assumptions: | ||||||||
Stock price | 3 | $ | 5.00 | |||||
Remaining term | 3 | 5 years | ||||||
Risk free rate | 2 | 0.62 | % | |||||
Expected volatility | 3 | 56.54 | % |
Fair value hierarchy of the above assumptions can be categorized as follows:
(1) | There were no Level 1 inputs. |
(2) | Level 2 inputs include: |
Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
(3) | Level 3 inputs include: |
Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).
Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
2014 Public Offering of Common Stock and Warrants
On January 29, 2014, the Company closed a public offering of 5,834,234 units at the price of $2.40 per unit for the total gross proceed of approximately $14.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.20 of a share of common stock (the “2014 Investor Warrants”). The 2014 Investor Warrants are exercisable at $3.00 per share and callable by the Company at $6.00 per share if certain conditions are met.
Placement Agent Fees
In connection with the 2014 Public Offering, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 7% of the gross proceeds from sale of the units, which resulted in a payment to the Placement Agent of an aggregate of $980,151 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received 175,027 warrants, or 3% of the aggregate number of shares sold in the offering (the “2014 Placement Agent Warrants” and together with the 2014 Investor Warrants, the “2014 Warrants”). Each 2014 Placement Agent Warrant entitles the Placement Agent to purchase one share of the Company’s common stock at $3.00 per share. The cash payment of the $980,151 2014 Placement Agent Fee and the $121,707 aggregated initial fair value of the 2014 Placement Agent Warrants (seeFair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.
Warrants
The 2014 Warrants are exercisable at any time commencing after January 29, 2014 (the “Initial Exercise Date”). Subject to the call right described above, the 2014 Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date on November 29, 2018 (the “Expiration Date”). The 2014 Warrants cannot be exercised on a cashless basis. There are no redemption features embodied in the 2014 Warrants and they have met the conditions provided in current accounting standards for equity classification.
Fair Value Consideration
The Company’s accounting for the issuance of the 2014 Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The 2014 Warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.
The 2014 Investor Warrants and the 2014 Placement Agent Warrants were valued at $834,986 or $0.72 per warrant, and $121,707 or $0.70 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the 2014 Warrants:
Fair | January 29, 2014 | |||||||||||
Value Hierarchy Level | 2014 Investor Warrants | Placement Agent Warrants | ||||||||||
Indexed shares | 1,166,849 | 175,027 | ||||||||||
Exercise price | $ | 3.00 | $ | 3.00 | ||||||||
Significant assumptions: | ||||||||||||
Stock price | 1 | $ | 2.50 | $ | 2.47 | |||||||
Remaining term | 3 | 5 years | 5 years | |||||||||
Risk free rate | 2 | 1.45 | % | 1.42 | % | |||||||
Expected volatility | 3 | 37.96 | % | 37.95 | % |
Fair value hierarchy of the above assumptions can be categorized as follows:
(1) | Level 1 inputs include: |
Stock price- The Fair value of Company’s common was derived from the closing prices in NASDAQ Capital Market as of the issuance.
(2) | Level 2 inputs include: |
Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
(3) | Level 3 inputs include: |
Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As of September 30, 2013,a result, as required by ASC 718-10-30, the Company has grantedaccounted for the warrants using the calculated value method. The Company identified five public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
Outstanding Warrants
As of March 31, 2014, warrants to purchase 58,5006,073,426 shares of common stock to the placement agent in connection with the financing facility with Aspire Capital. The warrants are exercisable at $5.80 or $5.70 per share and expire in 2017. An expense of $72,549 has been recognized during 2013 for issuance of these warrants.
4,292,050 warrants from the 2011 private placement (exercisable at $1.25 or $1.60), |
(2) | 325,000 warrants issued in theAcueity transaction (exercisable at $5.00), |
(3) | 1,166,849 warrants from the January 29, 2014 Public Offering (exercisable at $3.00), and |
(4) | 242,027 warrants granted as placement agent fees for the Company’s offerings during 2013 and January 29, 2014 (exercisable from $2.12 to $12.43). | |
(5) | 47,500 warrants granted to an outside consulting firm (exercisable at $4.24). |
Stock Options and Incentive Plan
On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, subject to stockholder approval, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 1,000,000 shares (or 2,263,320 shares prior to the reverse stock-split on September 28, 2010) were initially reserved for issuance in connection with awards granted under the 2010 Plan, such number of shares to be subject to adjustment as provided in the plan and in any award agreements entered into by the Company under the plan, and upon the exercise or conversion of any awards granted under the plan. On January 1, 2012, 450,275 shares were added to the 2010 Plan and on January 1, 2013, 500,000516,774 shares were added to the 2010 Plan, and on January 1, 2014, 742,973 shares were added to the 2010 plan as provided under the terms of the 2010 Plan.
The Company granted options to purchase 122,740 and 857,394334,397 shares of common stock to employees and directors during the three months ended March 31, 2014. During the quarter ended March 31, 2014, a new member of the Board of Directors was appointed and nine months ended September 30, 2013, respectively.in connection with that appointment he earned the right to receive 22,728 shares of restricted stock under the 2010 Plan; however, these shares were not issued as of March 31, 2014. The Company issued zero and 5,546no shares of common stocks in connection with the exercise of employee’s stock options during the three months and nine months ended September 30, 2013.March 31, 2014. As of September 30, 2013,March 31, 2014, there are 471,624897,617 options available for grant under the 2010 Plan.
NOTE 9: INCOME TAXES
The Company accounts for income taxes as outlined in ASC 740, “Income Taxes”, which was previously Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (“SFAS 109”). Under the asset and liability method of SFAS 109, deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of September 30, 2013March 31, 2014 and December 31, 20122013 due to the Company’s continuing operating losses.
NOTE 10: CONCENTRATION OF CREDIT RISK
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000.$250,000. At September 30, 2013March 31, 2014 and December 31, 2012,2013, the Company had $7,443,561$16,340,951 and $1,475,197$6,092,161 in excess of the FDIC insured limit, respectively.
NOTE 11: COMMITMENTS AND CONTINGENCIES
Lease Commitments
On March 4, 2011, the Company entered into a commercial lease agreement with Sanders Properties, LLC for office space located in Seattle, WA. The lease provides for monthly rent of $1,100$1,100 and a security deposit of $1,500.$1,500. The lease terms are from April 1, 2011 through March 31, 2014. For the nine months ended September 30, 2013,On March 20, 2014, the Company incurred $8,800entered into a new agreement with Sanders properties which extends the terms of the lease through March 31, 2015 with a monthly rent expense for the lease.
On December 9, 2011, the Company entered into another commercial lease agreement with Fred Hutchinson Research Center for lab and office space located in Seattle, WA. The lease provides for monthly rent of $16,395$16,395 for the period from February 24, 2012 to August 31, 2012, $19,923$19,923 for the period from September 1, 2012 to August 31, 2013, and $20,548$20,548 for the period from September 1, 2013 to November 29, 2014. The security deposit of $32,789$32,789 was paid in March 2012 and recorded as Security Deposit on the consolidated balance sheet as of December 31, 2012. For the nine months ended September 30, 2013, the Company incurred $233,260 of rent expense for the lease, which included leasing office management expenses.
On March 24, 2014, the Company entered into another commercial lease agreement with ARE LLC (Alexandria) for the Company’s laboratory space which extends the term of the existing lease with Fred Hutchison Research Center, which expires in November 2014, through November 30, 2016. The lease provides for monthly rent payments of $22,736 from December 2014 through November 2015 and $23,258 from December 2015 through November 2016. As of March 31, 2014, the Company incurred and recorded security deposits of $25,000.
The future minimum lease payments due subsequent to September 30, 2013March 31, 2014 under all non-cancelable operating leases for the next five years are as follows:
As of September 30, | Amount | |||
2014 | $ | 380,767 | ||
2015 | 62,451 | |||
2016 | - | |||
2017 | - | |||
2018 | - | |||
Thereafter | - | |||
Total minimum lease payments | $ | 443,218 |
As of December 31, | Amount | |||
2014 (remainder of the year) | $ | 247,939 | ||
2015 | 276,805 | |||
2016 | 255,845 | |||
2017 | - | |||
2018 | - | |||
Thereafter | - | |||
Total minimum lease payments | $ | 780,589 |
Affymetrix Purchase Commitment
In September 2013, the Company entered into an “Ownership“OwnerChip Program Agreement” with Affymetrix, Inc, a manufacturer of GeneChip Systems, where Affymetrix has agreed to loan a GeneChip System 3000Dx v.2 (“instrument”) to us if we purchase and take delivery of a minimum thirty GeneChip Human Genme U133 Plus 2.0 (30-pack) arrays at $21,590$21,590 per 30 pack for the next three years for a total purchase obligation of $647,700$647,700 with a minimum purchase of ten 30-pack arrays per contract year. At the end of the three year contract, upon fulfillment of the purchase commitment, the instrument title and ownership transfer to Atossa at no additional cost. In addition to the GeneChip Human Genme, we must purchase a two year service contract for $51,600$51,600 to cover maintenance of the instrument during the contract period. We placed an initial order for four 30-pack arrays in Septemberduring 2013 for $94,723.$94,723. We are obligated to purchase 26 additional arrays during the next three year contract term.
A5 Software Development Commitment
On June 10, 2013 the Company entered into an irrevocable license and service agreement with A5 Genetics KFT, Corporation, pursuant to which the Company received the world-wide (other than the European Union) exclusive license to the software used in the NextCYTE test. The Company has the right to prosecute patents related to this software, two of which the Company has filed in the United States. The patent applications have been assigned to us. The Company paid a one-time fee of $100,000 to A5 Genetics in 2013 and in March 2014 the Company completed software validation and paid an additional $100,000 to A5 Genetics. The Company is obligated to pay up to an additional $1.2 million to A5 Genetics upon the achievement of future milestones. The Company must also pay a royalty of $50 for each NextCYTE Test performed and $65 as a service fee for each NextCYTE Test performed. The agreement terminates on the later of the ten year anniversary of the agreement or the expiration of the latest to expire patent covering the software.
Contingencies
On June 30, 2011, Robert Kelly, the Company’s former President, filed a counterclaim against the Company in an arbitration proceeding, alleging breach of contract in connection with the termination of a consulting agreement between Mr. Kelly (dba Pitslayer LLC) and the Company that was entered into in July 2010 in connection with his resignation from the Company as President and a director. The consulting agreement was terminated by the Company in September 2010. Mr. Kelly seeks $450,000$450,000 in compensatory damages, which is the amount he claims would have been earned had the consulting agreement been fulfilled to completion.
On December 11, 2012, Mr. Kelly filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the termination of Mr. Kelly’s consulting contract and the rescission of shares issued to him in July 2010 in connection with his resignation from the Company as President and a director. The specific amount of damages sought is to be proven at trial and is not specified. On July 8, 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action was dismissed.
On February 26, 2013, Mr. Victor Cononi filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the rescission of shares issued to him in July 2010 in connection with Mr. Kelly’s resignation from the Company as President and a director. Mr. Cononi is the father of Mr. Kelly’s paramour. The specific amount of damages sought is to be proven at trial and is not specified. In August 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action was stayed pending resolution of the arbitration of the claims; however, Mr. Cononi has been dismissed.
A hearing in the arbitration has been postponed pending certain proceduresheld in the above Western Division action and may be delayed furtherabeyance to accommodate other third party civil and federal criminal proceedings alleging securities and wire fraud that have been brought against Mr. Kelly with respect to his prior employment and predating his service with the Company.
The Company is reasonably confident in its defenses to Mr. Kelly’s and Mr. Cononi’s claims. Consequently, no provision or liability has been recorded for these claims as of September 30, 2013.March 31, 2014. However, it is at least reasonably possible that the Company’s estimate of liability may change in the near term. Any payments by reason of an adverse determination in this matter will be charged to earnings in the period of determination.
On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.
On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel. The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation. No. 2:13-cv-01836-RSM. An amended complaint was filed on April 15, 2014.
We believe this complaintlawsuit is without merit and plan to defend ourselves vigorously. Failurevigorously; however, failure by us to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on our business, results of operations and financial condition. Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of September 30, 2013.March 31, 2014. The costs associated with defending and resolving the complaintlawsuit and ultimate outcome cannot be predicted. These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of our business, will depend upon many unknown factors and management’s view of these may change in the future.
FDA Warning Letter
On February 21, 2013, the Company received a Warning Letter (“Warning Letter”) from the FDA regarding its Mammary Aspirate Specimen Cytology Test (MASCT) System and MASCT System Collection Test (together, the “System”). The Warning Letter arises from certain FDA findings during a July 2012 inspection, to which the Company responded in August 2012, explaining why the Company believed it was in compliance with applicable regulations and/or was implementing changes responsive to the findings of the FDA inspection. The FDA alleges in the Warning Letter that following 510(k) clearance of the MASCT System, the Company changed the System in a manner that requires submission of an additional 510(k) notification to the FDA. Specifically, the FDA stated that the Instructions For Use (IFU) in the original 510(k) submission stated that the user must “Wash the collection membrane with fixative solution into the collection vial…” while the current IFU states “…apply one spray of Saccomanno’s Fixative to the collection membrane…” and that “this change fixes the NAF specimen to the filter paper rather than washing it into a collection vial.” At the time that the changes were made the Company determined and documented that the change could not significantly affect the safety or effectiveness of the MASCT System, and thus, that a new 510(k) was not required in accordance with the FDA’s guidance document entitled, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” The Warning Letter also identified certain issues with respect to the Company’s marketing of the System and the Company’s compliance with FDA Good Manufacturing Practices (cGMP) regulations, among other matters. The Company responded to the Warning Letter on March 13, 2013, and identified the corrective actions that had been made, or were otherwise underway The Company also filed a new 510(k) application for the MASCT System which was withdrawn in August 2013 after receiving feedback from the FDA.
On October 4, 2013, the Company initiated a voluntary recall of the system to address FDA’s concerns regarding the modifications identified in the Warning Letter. As a result of this recall, this product is currently not being marketed or distributed in the U.S. The Company plans to preparesubmitted a new premarket notification or 510(k) application for submission to the FDA on December 23, 2013 that covers the collection, preparation, and processing of NAF specimens at our laboratory and includes the spray method of fixing specimens to the collection membrane.
On March 14, 2014, the FDA completed a follow up inspection at our Seattle facility. A Form 483 was provided to be held on November 14, 2013. Onceus at the conclusion of the inspection. In the FDA's most recent Form 483, five inspectional observations were identified regarding our quality management system. The FDA inspector also orally identified five additional discussion points related to our product labeling prior to the recall of the MASCT System; sufficiency of the content of our pending 510(k) submission for the ForeCYTE Breast Aspirator; and other compliance issues. On March 26, 2014, we understand what types of datasubmitted a response to the FDA, is seeking, we intendwhich included our proposed corrective actions to submitaddress the 510(k) shortly after the meeting. Once filed we hope thatFDA's observations and discussion points. Whether the FDA will complete their reviewaccept our response is uncertain, particularly in light of the similar nature of certain of the current inspectional observations to previous inspectional observations. If the FDA does not agree with our submission within 90 days;proposed corrective actions, or accepts them but finds that we have not implemented them adequately, or if we otherwise are found to be out of course we cannot predict if they will ask uscompliance with applicable regulatory requirements at a later date, the FDA could initiate an enforcement action including additional warning letters, fines and penalties. The FDA also may not clear our pending 510(k) for additional informationthe ForeCYTE Breast Aspirator or otherwise complete their review withinour other devices and services under development. Any of the 90 days.
As of March 31, 2014, the Company has recorded a loss contingency as of September 30, 2013 of $402,840$96,201 in contingent liability and has incurred $339,042 in actual expenses related to the estimated costs of the recall, including the estimated costs of pursuing the additional 510(k) clearance. The recall and 510(k) process may take longer than expected and we may incur costs that we have not anticipated. Accordingly, the actual amount of the loss contingency may be higher than we currently expect.
NOTE 12: RELATED PARTY TRANSACTIONSSTOCK BASED COMPENSATION
In accordance with the guidance provided in ASC Topic 718, Stock Compensation (formerly SFAS 123R), the compensation costs associated with thesethe options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized a compensation expense of $1,187,716$230,181 and $96,251$274,511 for the ninethree months ended September 30,March 31, 2014 and 2013, and 2012, respectively.
The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:
2010 through December 2012 | Employee | Employee & Officers | Directors | CEO & CSO | |||||
Date of Grant | December 2012 | September 2011 | April 2012 – September 2011 | July 2010 | |||||
Fair value of common stock on date of grant | $4.11-$4.24(D) | $0.9060(B) | $0.9060 (B &C ) | $2.7560(A) | |||||
Exercise price of the options | $4.11 - $4.24 | $1.25 | $1.25-$6.00 | $5.00 | |||||
Expected life of the options (years) | 5.74 - 6.11 | 5.65 | 5.00 – 5.65 | 3.33 | |||||
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | |||||
Expected volatility | 42.44 – 44.58% | 53.90% | 53.90-62.46% | 58.59% | |||||
Risk-free interest rate | 0.91-0.99% | 1.08% | 0.89 – 1.08% | 1.03% | |||||
Expected forfeiture per year (%) | 10.00% | 10.00% | 0.00% | 0.00% | |||||
Weighted average fair value of the options per unit | $1.7426-$1.7842 | $0.3579 | $0.3579-$3.0367 | $0.6744 |
Year To Date September 2013 | Employee | Employee & Officers | Directors | CEO & CSO | |||||
Date of Grant | January - August 2013 | January - June 2013 | May 2013 | March 2013 | |||||
Fair value of common stock on date of grant(E) | $3.95 - $5.19(D ) | $4.11 - $4.58(D) | $6.59 (D) | $6.57 (D ) | |||||
Exercise price of the options | $3.95 - $5.19 | $4.11 - $4.58 | $6.59 | $6.57 | |||||
Expected life of the options (years) | 6.09 - 6.11 | 5.00 – 6.11 | 5.00 – 5.31 | 5.00 | |||||
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | |||||
Expected volatility | 40.73 - 40.92% | 40.96 - 41.05% | 41.06-41.09% | 47.09% | |||||
Risk-free interest rate | 1.73 -1.97% | 1.03-1.36% | 0.73 - 0.84% | 1.13% | |||||
Expected forfeiture per year (%) | 10.00% | 10.00% | 10.00% | 0.00% | |||||
Weighted average fair value of the options per unit | $1.35 - $2.18 | $1.69 - $1.89 | $2.41 - $2.49 | $2.70 |
Year Ended December 2013 | Employees | Employees & Officers | Directors | CEO & CSO | ||||||||||||
Date of Grant | January - December 2013 | January - June 2013 | May & October 2013 | March 2013 | ||||||||||||
Fair value of common stock on date of grant (A) | $2.05 - $5.19 | $4.11 - $4.58 | $2.04 - $6.59 | $ | 6.57 | |||||||||||
Exercise price of the options | $2.05 - $5.19 | $4.11 - $4.58 | $2.04 - $6.59 | $ | 6.57 | |||||||||||
Expected life of the options (years) | 6.09 - 6.11 | 5.00 – 6.11 | 5.00 – 5.31 | 5.00 | ||||||||||||
Dividend yield | 0.00 | % | 0.00 | % | 0.00 | % | 0.00 | % | ||||||||
Expected volatility | 40.73 – 41.81 | % | 40.96 - 41.05 | % | 41.06-41.53 | % | 47.09 | % | ||||||||
Risk-free interest rate | 1.73 -1.97 | % | 1.03-1.36 | % | 0.73 - 1.49 | % | 1.13 | % | ||||||||
Expected forfeiture per year (%) | 10.00 | % | 10.00 | % | 10.00 | % | 0.00 | % | ||||||||
Weighted average fair value of the options per unit | $0.878 - $2.18 | $1.69 - $1.89 | $0.790 - $2.49 | $ | 2.70 |
Three Months Ended March 2014 | Employees | Officers | Directors | |||||||||
Date of Grant | January 8, 2014 | January 8, 2014 | March 1, 2014 | |||||||||
Fair value of common stock on date of grant(A) | $ | 2.20 | $ | 2.20 | $ | 2.20 | ||||||
Exercise price of the options | $ | 2.20 | $ | 2.20 | $ | 2.20 | ||||||
Expected life of the options (years) | 6.06 | 6.06 | 5.09 | |||||||||
Dividend yield | 0.00 | % | 0.00 | % | 0.00 | % | ||||||
Expected volatility | 41.70- 41.72 | % | 41.70 | % | 38.68 | % | ||||||
Risk-free interest rate | 2.11 | % | 2.11 | % | 1.53 | % | ||||||
Expected forfeiture per year (%) | 10.00 | % | 10.00 | % | 10.00 | % | ||||||
Weighted average fair value of the options per unit | $ | 0.95 | $ | 0.95 | $ | 0.80 |
(A) |
The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant. |
Fair value hierarchy of the Company were unable to finance the Company at the level needed for growth. The withdrawal of the Registration Statement in February 2011 further weakened the impression of the Company in the market. The fair value of the Company’s common stock decreased from $2.756 in 2010 to $0.906 in 2011 primarily because the grants in 2011 relied on the arm’s-length negotiation of the private placement financing (for illiquid stock)above assumptions can be categorized as opposed to relying on an anticipated initial public offering (of publicly-traded stock), as was the case in 2010. The private placement transactions were between the company and over 200 accredited investors and ascribed a value of $0.906 to the Company’s common stock.
Level 1 inputs include: |
Stock price- The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
(2) | Level 2 inputs include: |
Risk-free rate-
The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the options.(3) | Level 3 inputs include: |
Expected lives- The expected lives of options granted were derived from the output of the option valuation model and represented the period of time that options granted are expected to be outstanding.
Expected forfeitures per year- The expected forfeitures are estimated at the dates of grant and will be revised in subsequent periods pursuant to actual forfeitures, if significantly different from the previous estimates.
Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result,
as required by ASC 718-10-30, the Company has accounted for the options using the calculated value method. The Company identified five to seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.The estimates of fair value from the model are theoretical values of stock options and changes in the assumptions used in the model could result in materially different fair value estimates. The actual value of the stock options will depend on the market value of the Company’s common stock when the stock options are exercised.
Options issued and outstanding as of September 30, 2013March 31, 2014 and their activities during the ninethree months then ended are as follows:
Number of Underlying Shares | Weighted- Average Exercise Price Per Share | Weighted- Average Contractual Life Remaining in Years | ||||||||
Outstanding as of January 1, 2013 | 1,052,137 | $ | 3.79 | |||||||
Granted | 1,425,394 | 5.02 | ||||||||
Expired | (3,812) | 4.99 | ||||||||
Forfeited | (221,522) | 4.21 | ||||||||
Exercised | (5,546) | 1.79 | ||||||||
Outstanding as of September 30, 2013 | 2,246,651 | 4.53 | 8.87 | |||||||
Exercisable as of September 30, 2013 | 1,044,549 | 4.54 | 8.21 | |||||||
Vested and expected to vest (1) | 2,090,475 | 4.54 | 8.83 |
Number of Underlying Shares | Weighted- Average Exercise Price Per Share | Weighted- Average Contractual Life Remaining in Years | Aggregate Intrinsic Value | |||||||||||||
Outstanding as of January 1, 2014 | 2,282,719 | $ | 4.43 | |||||||||||||
Granted | 311,669 | $ | 2.20 | |||||||||||||
Expired | - | $ | - | |||||||||||||
Forfeited | (61,221 | ) | $ | 4.70 | ||||||||||||
Exercised | - | $ | - | |||||||||||||
Outstanding as of March 31, 2014 | 2,533,167 | $ | 4.15 | 7.86 | $ | 107,800 | ||||||||||
Exercisable as of March 31, 2014 | 1,253,137 | $ | 4.47 | 6.52 | $ | 107,800 | ||||||||||
Vested and expected to vest (1) | 2,355,778 | $ | 4.18 | 7.76 | $ | 107,800 |
(1) vested shares and unvested shares after a forfeiture rate is applied.
Issuance of September 30,Restricted Common Stock for Director’s Compensation
On October 10, 2013, and December 31, 2012, the aggregate intrinsic value of options outstanding was $3,604,669 and $1,150,416, respectively.
On March 1, 2014, the Company agreed to issue 22,728 shares of restricted stock with a grant date value of $50,000 or $2.20 per share to a new board member; however these shares have not been issued as of March 31, 2014. The restriction will be removed as shares vest quarterly for a proportional number of granted shares over the first year of service on the board, and the grant date value of such shares will be expensed in the quarter the restriction is removed.
For the three months ended March 31, 2014, $230,181 was recorded as stock compensation expenses, including $16,611 for restricted stock.
NOTE 13: SUBSEQUENT EVENTS
Management has evaluated subsequent events through May 14, 2014, the date which the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2014 have been incorporated into these consolidated financial statements, and besides the disclosures herein, there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events”.
On May 6, 2014, the Board of Directors of the Company approved the following changes to the compensation arrangements of the Company’s named executive officers for fiscal year 2014:
Name | Title | Annual base salary | Annual bonus potential as a % of base salary | Stock option grant | ||||||||||
Steven C. Quay, Ph.D., M.D. | Chief Executive Officer and President | $ | 500,000 | 50 | % | 250,000 | ||||||||
Kyle Guse, CPA, J.D. | Chief Financial Officer, General Counsel and Secretary | $ | 350,000 | 45 | % | 200,000 | ||||||||
Shu-Chih Chen, Ph.D. | Chief Scientific Officer and Director of Human Resources | $ | 350,000 | 40 | % | 125,000 |
The stock options were granted under the Company’s 2010 Stock Option and Incentive Plan. The options have an exercise price of $1.22, which is the fair market value on the date of grant, and vest quarterly over four years so long as the executive remains employed with the Company. The options are otherwise subject to the terms and conditions of the employment agreements with the executives.
In addition to the foregoing named executive officers, certain other senior officers received salary adjustments on May 6, 2014 for the 2014 fiscal year totaling $143,438 for the quarter ended March 31, 2014. The estimated expense of those salary adjustments has been accrued as of March 31, 2014.
On May 6, 2014, options to purchase a total of 150,000 shares of common stock valued at $5.00 per share,were also granted under the offering price listed on the prospectus filed pursuant2010 plan to Rule 424(b)(4) on November 9, 2012,non-employee directors and warrants to purchase up to 325,000 shares of common stock atcertain senior officers. The options have an exercise price of $5.00 per share,$1.22 which was the fair market value on the date of grant. the options granted to non- employee directors vest quarterly over one year and options granted to the shareholders of Acueity, subject to a six-month lock up agreement which has since lapsed. The warrants, which have a five-year term, do not have a cashless exercise provision. The warrants were valued at $2.3457 per warrant, using a Black-Scholes-Merton Valuation Technique because it embodies allsenior officers vest quarterly over four years. As of the requisite assumptions (including trading volatility, estimated terms and risk-free rates) necessary to determinedate of filing this report, management was still in the process of determining the fair value of the warrants (see Note 8). There are no future financial obligations from the Company to Acueity from the commercialization of the acquired assets.
The purpose of this voluntary recall is to address concerns raised by the FDA in a Warning Letter received by Atossa in February 2013. In that Warning Letter, the FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the NAF specimen collection process identified in the current IFU. We are in the process of removing existing product from the market.ITEM 2.
The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. This discussion contains forward-looking statements, which are based on assumptions about the future of the Company's business. The actual results could differ materially from those contained in the forward-looking statements. Please read “Forward-Looking Statements” included below for additional information regarding forward-looking statements.
Forward-Looking Statements
This report contains, in addition to historical information, certain information, assumptions and discussions that may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the date of this report, we cannot assure you that the forward-looking statements set out in this report will prove to be accurate. We typically identify these forward-looking statements by the use of forward-looking words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or the negative version of those words or other comparable words. Forward-looking statements contained in this report include, but are not limited to, statements about:
the estimated costs associated with our product recall; | ||
These and other forward-looking statements made in this report are presented as of the date on which the statements are made. We have included important factors in the cautionary statements included in this report, particularly in the section entitled “Risk Factors,titled “RISK FACTORS,” that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events or circumstances that may affect our business after the date of this report. Except as required by law, we do not intend to update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future events or circumstances or otherwise.
Company Overview
We are a healthcare company focused on improving breast health. We are developinghealth through the development of a suite of tests and therapeutic medical devices, laboratory developed tests (LDTs), medical devices and services (LDT and/or invitro diagnostics) thattherapeutics. Our laboratory tests are being developed by our subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of cells in nipple aspirate fluid (NAF),; the cytological analysis of cells in ductal lavage fluid collected from each individual breast duct with manual breast ductour proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in formalin-fixed paraffin embedded breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells.
Our medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States.) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. Our ForeCYTE Breast Aspirator (previously called the MASCT System) was launched nationally in early 2013 and was recalled in October 2013. It will not be re-launched in the United States unless and until we receive additional regulatory clearance from the FDA. We submitted a new 510(k) for the ForeCYTE Breast Aspirator on December 23, 2013; we received questions from the FDA regarding this submission on February 28, 2014 and are in process of addressing such questions as of the date of this report.
We plan to develop certain of our medical devices and laboratory tests so that they can be used as companions to pharmaceutical therapies. For example, we plan to develop our patented intra ductal microcatheters for the potential delivery of a pharmaceutical targeted to a condition called ductal carcinoma in-situ (DCIS). We also have a therapeutic programplan to provide targeted, localizeddevelop our medical devices and laboratory tests as companion diagnostics to pharmaceutical therapies to treat women at high risk of breast cancer and for the treatment of cancerousproliferative epithelial disease (PED). These programs are in the early pre-clinical stage and pre-cancerous conditionswill require testing and approval and/or clearance from the FDA prior to commercialization.
Our strategy consists of the following:
(1) Re-launch ForeCYTE: We hope to obtain FDA clearance for the ForeCYTE Breast Aspirator, our lead medical device, and, if FDA clearance is obtained to re-launch it in the United States through a direct sales force and our distributors, including Fisher Healthcare and PSS McKesson. We also intend to introduce the ForeCYTE Breast Aspirator into one or more foreign markets.
(2) Introduce our other Laboratory Tests and other Medical Devices along the Care Path: We plan to make each of NRLBH’s individual laboratory tests and medical devices available to healthcare providers by completing any necessary development and obtaining any necessary regulatory clearances and/or approvals.
(3) Develop Pharmaceutical Therapies to be used as Companions with our Devices and Laboratory Services: We plan to develop our patented microcatheters. microcatheters to deliver pharmaceuticals to initially treat DCIS. We also plan to develop our devices and laboratory services for use as companion diagnostics. For example, we intend to use our devices to collect specimens of NAF, test the NAF specimens in our laboratory, provide pharmaceutical treatment options for the breast health conditions detected by our tests and then use our medical devices to monitor treatment response. We expect that these companion diagnostic systems will initially target PED and/or high risk women and will require lengthy and costly clinical trials that we will undertake only with input and direction from the FDA.
(4) Advance Partnering Opportunities: We plan to work with third parties and partners to develop our business. For example, we plan to work with Fisher Healthcare and PSS McKesson to distribute the ForeCYTE Breast Aspirator and we may partner with one or more laboratories to act as NAF collection sites using our ForeCYTE Breast Aspirator if and when it is cleared by the FDA. We plan to retain clinical research organizations (CROs) for clinical development of potential therapeutic programs and we intend to partner with pharmaceutical companies to develop companion diagnostic systems, which may include therapeutics to treat PED, DCIS and/or high risk women.
(5) Promote Physician and Patient Awareness: Our products and services are highly innovative and gaining adoption will require that physicians change the way they practice medicine. To facilitate adoption, we will continue to educate physicians and patients by engaging key opinion leaders, publishing in peer reviewed journals, and working with patient advocacy groups.
All of our productsmedical devices and servicesthe NRLBH’s laboratory tests, as well as the breast health companion diagnostic systems, are currently under development and are awaitingwe must receive additional regulatory clearances and/or approvals prior to marketing and commercialization. Our products and services under development include:
Our leading test,device, the MASCT System (which we currently refer to as the ForeCYTE Breast Health Test, wasAspirator), and our NAF cytology test, were launched in a “field experience” trial in 2012 and nationally in the beginning of 2013. In October 2013, we voluntarily recalled the MASCT System to address concerns raised by the FDA in a Warning Letter we received in February 2013. In December 2013, we submitted a pre- market notification to the FDA for a 510(k) clearance for the ForeCYTE Breast Health Test (also knownAspirator, and on February 28, 2014, we received questions from the FDA regarding this submission which we are in the process of addressing as of the MASCT System or ForeCYTE Test).date of this report. As a result of this recall, we are not currently marketing this product in the U.S. WeIf we obtain clearance from the FDA, we intend to obtain an additional FDA 510(k) clearance for the ForeCYTE Test and to re-launch the test upon receiving regulatory clearance.ForeCYTE Breast Aspirator and our NAF cytology test. However, the regulatory pathway to obtaining a 510(k) clearance can be lengthy, expensive and unpredictable; we therefore cannot provide any assurances that we will receive a new 510(k) clearance for ForeCYTE Breast Aspirator or any of our other tests under development in a timely fashion or at all.
The NRLBH has been certified pursuant to the Clinical Laboratory Improvement Amendments, or CLIA. CLIA certification is legally required to receive reimbursement from federal or state medical benefit programs, like Medicare and Medicaid, and is a practical requirement for most third-party insurance benefit programs. Our CLIA-certified laboratory, which is permitted to accept samples from all 50 states under its CLIA certification, its state licenses, or, in New York under recognized exemption provisions while its license application is pending, examines the NAF specimens by cytological analysis.
On April 30, 2013, we entered into a Distribution and Marketing Services Agreement with Millennium Medical Devices LLC, pursuant to which, once we receive any necessary FDA clearances, Millennium will market and distribute the ForeCYTE breast health test kitsBreast Aspirator in New York City and Northern New Jersey. In May 2013, we entered into a distribution agreement with Fisher Healthcare, a division of Fisher Scientific Company, LLC, and in September 2013, we entered into a distribution agreement with McKesson Medical Surgical.
From our inception (April 30, 2009) through our recall in October, 2013, we have received, processed, and reported the results to physicians from approximately 2,808 NAF samples processed and reported with our NAF cytology test (representing 1,404 patients). From inception through March 31, 2014, we have generated $1,140,024 in product and service revenue. We incurred net losses of $2,411,531 for the three months ended March 31, 2014 and $22,928,145 since inception. We have not yet established an ongoing source of revenue sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on obtaining adequate capital to fund operating losses until we become profitable. We plan to obtain additional capital resources by: selling our equity securities; if cleared by the FDA, selling the ForeCYTE Breast Aspirator and generating laboratory service revenue from our tests performed by the NRLBH; and borrowing from stockholders or others when needed. However, we cannot assure you that we will be successful in accomplishing any of these plans and, if we are unable to obtain adequate capital, we could be forced to cease operations.
Our Voluntary Product Recall
On October 4, 2013, we initiated a voluntary recall to remove the ForeCYTE Breast Health Test andMASCT device (which was also called the MASCT device“ForeCYTE Test” prior to the recall) from the market. This voluntary recall includes the MASCT System Kit and Patient Sample Kit. The vast majority of these products (approximately ninety percent) arewere in inventory with our distributors and the remaining quantities arewere at customer sites across the United States. Distributors and customers haveAs of the date of this report, the recall has been instructed to stop using affected products and return them to Atossa immediately.
The purpose of this voluntary recall is to address concerns raised by the FDA in a Warning Letter received by Atossa in February 2013. In that Warning Letter, the FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the NAF specimen collection process identified in the current IFU. We are in the process of removing existing product from the market.
The MASCT device was originally cleared by the FDA for use as a sample collection device, with the provision that the fluid collected using this device can be used to determine and/or differentiate between normal, pre-cancerous,pre-malignant, and cancerousmalignant cells. The MASCT device has not been cleared by the FDA for the screening or diagnosis of breast cancer. In addition, the ForeCYTE Breast Health Testour NAF cytology test has not been cleared or approved by the FDA for any indication as the company considered this to be a Laboratory Developed Test – or within a class of tests that has historically not required a 510(k)s for. The ForeCYTE Breast Health Test application. Our NAF cytology test and the MASCT device are not intended to serve as a replacement for screening mammograms, diagnostic imaging tests, or biopsies. Patients are instructed to follow the recommendations and instructions of their physician with respect to breast cancer screening and diagnosis.
To date, we are unaware of any adverse incidents or injuries associated with the use of the ForeCYTE Breast Healthour NAF cytology test and the MASCT device or the processing method identified in the latest version of the IFU. Additionally, we are unaware of any risk to health or injury for clinicians or the patient population that have used these devices. However, there is a risk that these devices may produce false positive or false negative results. Although not cleared or intended for this use, if these devices are used as a substitute for recommended screening or diagnosis of breast cancer, FDA is concerned that patients may choose to forgo recommended mammograms and necessary biopsies.
We are working withsubmitted a new 510(k) application to the FDA on this matter and this voluntary recall.December 23, 2013 for the ForeCYTE Breast Aspirator which is intended for use in the collection of nipple aspirate fluid for cytological testing. On February 28, 2014, we received a request from the FDA to submit additional information in support of the application. We have notified distributors and customers by certified mail and we are arranging for the return of all recalled products. As of the date of this report, approximately 8% of the MASCT pumps and 84% of the MASCT patient collection kits have been returneduntil August 20, 2014 to our processing center. We also plan to prepare a new premarket notification or 510(k) application for submissionrespond to the FDA that covers the collection, preparation, and processing of NAF specimens at our laboratory and includes the spray method of fixing specimens to the collection membrane. However, weFDA. We cannot market or distribute the modified product inForeCYTE Breast Aspirator within the U.S. unless orUnited States until the new 510(k) is cleared bywe receive clearance for this device from the FDA.
As of March 31, 2014, we have requested a pre-submission meeting with the FDA. This meeting is scheduled to be held on November 14, 2013. Once we understand what typesincurred cumulative actual recall expenses of data the FDA is seeking, we intend to submit the 510(k) shortly after the meeting. Once filed we hope that the FDA will complete their review of our submission within 90 days; but of course we cannot predict if they will ask us for additional information or otherwise complete their review within the 90 days.
If and when we re-launch our ForeCYTE Test,Breast Aspirator, we will incur additional sales and marketing expenses. We will need to revise our sales and marketing tools and continue hiring direct sales employees in an effort to build a regional, and ultimately national, sales force. We also expect to continue to hire clinical consultants to help healthcare providers begin to use our ForeCYTE Test.
Follow-up FDA Inspection
On March 14, 2014, the FDA completed a follow up inspection at our Seattle facility. A Form 483 was provided to Aspire underus at the purchase agreement. The Company agreed to file an initial registration statement registering the saleconclusion of the shares by Aspire withinspection. In the SEC within 10 days of entering into the purchase agreement with Aspire. We further agreedFDA's most recent Form 483, five inspectional observations were identified regarding our quality management system. The FDA inspector also verbally identified five additional discussion points related to keep the registration statement effective and to indemnify Aspire for liabilities in connection with the sale of the shares under the terms of the registration rights agreement.
Revenue Sources
The commercialization of the ForeCYTE TestMASCT System and NAF cytology test has provided us with two revenue sources: (i) sales-based revenue from the sale of the MASCT System device and patient kits to distributors, physicians, breast health clinics, and mammography clinics and (ii) service, or use-based, revenue from the preparation and interpretation of the NAF samples sent to our laboratory for analysis. The commercialization ofWe do not anticipate generating revenue until and unless we receive an additional 510(k) clearance from the ArgusCYTE test provides only laboratory service revenue.
Commercial Lease Agreements
On March 4, 2011, the Company entered into a commercial lease agreement with Sanders Properties, LLC for office space located in Seattle, WA. The lease terminated on March 31, 2014 and provides for monthly rent of $1,100 and a security deposit of $1,500. TheOn March 20, 2014, the Company entered into a new agreement with Sanders properties which extends the terms of the lease terms are from April 1, 2011 through March 31, 2014. For the nine months and three months ended September 30, 2013, the Company incurred $8,800 and $3,3002015 with a monthly rent of rent expense, respectively, for the lease.
On December 9, 2011, the Company entered into another commercial lease agreement with Fred Hutchinson Research Center for lab and office space located in Seattle, WA. The lease provides for monthly rent of $16,395 for the period from February 24, 2012 to August 31, 2012, $19,923 for the period from September 1, 2012 to August 31, 2013, and $20,548 for the period from September 1, 2013 to November 29, 2014. The security deposit of $32,789 was paid in March 2012 and recorded as Security Deposit on the consolidated balance sheet. For the three months and nine months ended September 30, 2013, the Company incurred $87,521 and $251,659 of rent expense, respectively, which included leasing office management expenses.
On March 24, 2014, the Company entered into another commercial lease agreement with ARE LLC (Alexandria) for the Company’s laboratory space which extends the term of the existing lease with Fred Hutchison Research Center which expires in November 2014 through November 30, 2016. The lease provides for monthly rent payments of $22,736 from December 2014 through November 2015 and $23,258 from December 2015 through November 2016. As of March 31, 2014, the Company incurred and recorded security deposits of $25,000.
We expect that these new laboratory facilities will be sufficient to meet our needs for the foreseeable future and we do not expect to need additional laboratory space for at least the next 24 months. We may need to secure additional office space as we grow our sales and marketing force and add to our administrative staff. Additional office space is readily available in our local market and we believe we can rent when necessary additional office space on acceptable terms.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates.
While our significant accounting policies are more fully described in Note 3 to our financial statements, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.
Revenue Recognition:
Overview
We will recognize product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) our price to the customer is fixed or determinable, and (iv) collection is reasonably assured.
Product Revenue
We recognize revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as we have an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. We will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, we will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.
Service Revenue
We record revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts will generally be used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history. We estimate we will utilize the
Cost of Revenue:
Cost of revenue consists of cost of diagnostic testing services and cost of product sales. Cost of diagnostic testing services primarily includes direct cost of material, direct labor, equipment, and shipping to process the patient samples (including pathology, quality control analysis, and shipping charges to transport tissue sample) in our laboratory. Costs associated with performing the Company's tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue historywas recognized with respect to determine a proper allowancethat test. Cost of product sales primarily includes manufacturing cost of our MASCT System for doubtful accounts beginning in 2014.
Cash and Cash Equivalents:
Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Accounts ReceivableReceivable:
Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts and bad debt expenses as of September 30, 2013March 31, 2014 and December 31, 20122013 was $228,841$382,721 and $0,$354,861, respectively.
InventoryInventory:
The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Because the sales price of the MASCT System was substantially lower than its cost for the nine months ended September 30, 2013 and since inception through September 30, 2013, resulting in the net realizable value of the MASCT System being determined at zero as of the balance sheet dates through taking the average sales price subtracted by selling expenses per unit, $0 and $121,910 of loss on reduction of inventory to the lower of cost or market was assessed and recorded as of September 30, 2013 and since inception through September 30, 2013, respectively. Additionally, managementManagement periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. During the course of our recall commenced in October 2013, we have recalled a substantial number of MASCT Systems. Based on management’s assessment of those devices and the pending FDA clearance, management decided to establish 100% allowance for valuation reserve on all MASCT Systems, and recorded $149,946 of losses on obsolete inventory as of and for the year ended December 31, 2013. During the quarter ended March 31, 2014 management identified no additional slow moving or obsolete inventory. The Company outsources product manufacturing to outside manufacturer contactors. The ownership of the goods transfers from the manufacturer to the Company’s customer at the time the products are shipped to the customers. As of September 30,March 31, 2014 and December 31, 2013, we had no inventory.
The Company provides, either directly or through distributors, the ForeCYTENAF cytology testing specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the CompanyNRLBH or other laboratories for diagnostic analysis. These collection kits are considered part of the MASCT System. During the initial marketing phase, in 2012, the Company distributedwe decided to distribute the kits to customers at no cost and bundledbundle them with the MASCT System,pumps, and has not intended to deem the collection kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Property, plant, and equipment:
Property, plant and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations
The Company applies the provisions of FASB ASC Topic 360 (ASC 360), “Property, Plant, and Equipment” which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360, at least on an annual basis. ASC 360 requires the impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the three months ended March 31, 2014 and year ended December 31, 2013 $0 and $158,292 was assessed and recorded as impairment on long-life assets.
Intangible AssetsAssets:
Intangible assets consist of intellectual property and software acquired. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.
Share-Based PaymentsPayments:
In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment,” which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation — Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.
We have fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.
Results of Operations
Three Months Ended March 31, 2014 and Nine Months Ended September 30, 2013 and 2012
Revenue and Cost of Goods Sold. For the three months ended September 30, 2013,March 31, 2014, revenue totaled $76,597,$24,124, consisting of $72,187 diagnostic testing serviceadditional cash collected in excess of the amounts we accrued previously at the Medicare rates. Total revenue from our ForeCYTE testing services and $4,410 in product sales revenue from sales of ForeCYTE kits and MASCT Systems. This represents a decrease of $28, 979, or 27 %, from the total revenue of $105,576 for the three months ended September 30, 2012. RevenueMarch 31, 2013 was $182,670, consisting of $169,230 in diagnostic service revenue and $13,440 for product sales. Cost of revenue totaled $0 for the ninethree months ended September 30, 2013March 31, 2014, compared to $66,464 in the same periods in 2013. The Company has recognized virtually no revenue or cost of revenue since the voluntary recall in October 2013.
For the three months ended March 31, 2014, gross profit totaled $585,345, consisting of $361,905 in diagnostic testing and $223,440 in product sales, an increase of $201,959, or 53%, from the total revenue of $383,386$24,124, compared to $116,206 in the same period in 2012. The growth in revenue is mainly due to $205,590 in product sales to Millennium for the initial purchase of 10,000 ForeCYTE kits.
Operating Expenses. For the three months ended September 30, 2013,March 31, 2014, total operating expenses were $3, 552,556$2,435,049 consisting of G&A expenses of $2, 858,027,$1,774,708, research and development expenses of $321,111,$422,503, and selling expenses of $373,418,$237,838, representing an increase of $2, 326,385,$377,410, or 190%18% from $1,226,171$2,057,639 in the same period in 2012,2013, consisting of G&A expenses of $548,108,$1,564,872, research and development expenses of $590,359,$220,192, and selling expenses of $87,704. For the nine months ended September 30, 2013, total operating expenses were $8,297,460, consisting of G&A expenses of $6,600,819, research and development expenses of $731,258, and selling expenses of $965,383, an increase of $4,610,291,or 125% , from total operating expenses of $3,687,169 in nine months ended September 30, 2012.
We expect that our G&A and selling expenses will continue to increase in the foreseeable future, and that if we successfully launchrelaunch the MASCT SystemForeCYTE Breast Aspirator and our related laboratory service offerings, we would also begin to incur additional sales and marketing expenses as we continue building a regional, and ultimately national, sales force. The Company also expected to incur additional sales and marketing expenses when if and when it receives additional FDA 510(k) clearance for its ForeCYTE Test and re-launches the test.
General and Administrative Expenses.Selling ExpensesG&A. Selling expenses for the three months ended September 30, 2013March 31, 2014 were $2,858,027, an increase$237,838, a decrease of $2, 267,668,$34,737, or 384%13%, from $590,359 in the same period in 2012. The G&A expenses$272,575 for the three months ended September 30, 2013 consisted primarily of $581,591 in salaries and bonusMarch 31, 2013. Selling expense $155,558 in legal and regulatory expense, $193,671 in consulting expense, $435,243 in estimated recall expenses ($402,840 in contingent liabilities and $32,403 in actual expenses), $228,841 in bad debt expenses, $67,141 in travel expense, $88,263 in insurance expense, and $248,759 in marketing expenses. G&A expenses for the nine months ended September 30, 2013 were $6,600,819, an increase of $4,704,565, or 248%, from $1,896,254 for the nine months ended 2012. The G&A expenses for the nine months ended September 2013 consisted of $1,548,899 in salaries and bonus expense, $428,872 in capital raising fees, $622,581 in legal and regulatory expenses, $646,548 in consulting expense, $435,243 in estimated recall expenses ($402,840 in contingent liabilities and $32,403 in actual expenses), $228,841 in bad debt expenses, $135,686 in travel expense, $247,774 in insurance expense, $250,109 in marketing expenses, and $462,029 in Board of Directors annual fees primarily related to expenses associated with stock option grants for service on the Board in 2012 and 2013.
Selling ExpensesGeneral and Administrative Expenses.. Selling G&A expenses for the three months ended September 30, 2013March 31, 2014 were $373,418,$1,774,708, an increase of $285,714,$209,836, or 326%13%, from $87,704$1,564,872 in the same period in 2013. The G&A expenses for the three months ended September 30, 2012. Selling expenseMarch 31, 2014 consisted primarily of $665,136 in salaries and bonus expenses, $238,497 in legal and regulatory expenses, $169,763 in consulting expenses, $44,026 in travel expenses, and $132,792 in insurance expenses. G&A expenses for the three months ended September 30,March 31, 2013 were $1,564,872 which primarily consisted primarily of $52,237 in selling and marketing professional fees, $205,875$545,793 in salaries $22,500and bonus expenses, $177,947 in advertising,legal expenses, $279,286 in consulting and $92,349professional fee expenses, $76,634 in patient collection kits providedaccounting expenses, $20,485 in travel expense, $42,041 in payroll taxes, and $93,374 in insurance expenses.
The increase in 2014 G&A expenses over 2013 was primarily attributable to physicians without charge. Selling expenses for the nine months ended September 30, 2013 were $965,383, an increase of $683,412, or 242%, from $281,971 for the same period in 2012. Selling expense for the nine months ended September 30, 2013 consisted primarily of $384,893 in selling and marketing professional fees, $405,474 in salaries $81,587 in advertising, and $92,349 in patient collection kits providedemployees benefits, travel expenses, cost of insurance, and legal and professional fees. We expect our G&A expenses to physicians without charge. Selling expenses increasedcontinue to grow as we hire additional administrative and manufacturing personnel as we prepare for and execute on the relaunch of the ForeCYTE Breast Aspirator, and our other products under development and as we incur additional costs associated with being a result of increased sales and marketing expenses paid to one of our distributors, and increased salaries and other selling and marketing expenses related to the national launch of ForeCYTE.
Liquidity and Capital Resources
We have a history of operating losses as we have focused our efforts on raising capital and building the MASCT System. The report of our independent auditors issued on our consolidated financial statements as of and for the years ended December 31, 20122013 and 20112012 expresses substantial doubt about our ability to continue as a going concern. In 2011, we were successful in raising net proceeds of $5.7 million through a private placement in order to fund the growth of our operations and product development. In November 2012 we were successful in our initial public offering and raising net proceeds of approximately $3.5 million.
On March 27, 2013, we entered into a stock purchase agreement with Aspire Capital Fund, LLC, which providesand pursuant to that upon the terms and subject to the conditions and limitations set forth therein, Aspire is committed to purchase up to an aggregate of $30 million of shares of ouragreement we sold common stock over the three-year term of the agreement. Under the agreement,to Aspire purchased $1,000,000 of our common stock onfrom March 27, 2013 for $12 per share and since that date through November 7,October 2013 Aspire has purchased an additional 2,150,000 shares of our common stock for a total aggregate purchase price of $10,303,745.$11,303,745. On November 8, 2013, we terminated this stock purchase agreement and entered into a new agreement with Aspire which provides that we may sell common stock to Aspire under the terms and subject to the conditions and limitations set forth therein. Under the new agreement, Aspire is committed to purchase up to an aggregate of $25 million of shares of our common stock over the 30 month term of the new agreement. One condition to utilizing the new agreement and sellingOn December 23, 2013, we sold $1 million of common stock to Aspire isunder this new agreement so that we fileup to a registration statement with the SEC covering the resaletotal of $24 million remains available for sale to them as of the sharesdate of this report. However, in connection with our January 2014 public offering we agreed not to be soldutilize the financing arrangement with Aspire for 120 days following completion of that offering.
On January 29, 2014, we closed a public offering of 5,834,234 units at the price of $2.40 per unit, with each unit consisting of one share of common stock and a warrant to Aspirepurchase 0.20 a share of common stock, for gross proceeds of approximately $14.0 million. The warrants are exercisable at $3.00 per share and thatare callable by us if and when the registration statement be declaredtrading price of our common stock is $6.00 per share over a defined period and remain effective.
Our ability to continue as a going concern is dependent on our obtaining additional adequate capital to fund additional operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease operations.
Cash Flows
For the ninethree months ended September 30, 2013,March 31, 2014, we incurred a net loss of $8,026,984.$2,411,531. Net cash used in operating activities was $6,182,060,$2,603,989, net cash used in investing activities was $400,674$102,966 and net cash provided by financing activities was $12,551,098. For the for the nine months ended September 30, 2012, we incurred a net loss of $3,374,249, net cash used in operating activities was $1,967,626, net cash used in investing actives was $0 and net cash used by financing activities was $475,375.
Funding Requirements
We expect to incur substantial expenses and generate ongoing operating losses for the foreseeable future as we prepare for the scale-up manufacturing and ongoing launchrelaunch of the MASCT System,ForeCYTE Breast Aspirator, complete the development of and launch the FullCYTEArgusCYTE test and NextCYTE Tests,tests, and buildother devices in the pipeline and operatestart the development of our planned diagnostics laboratory in the Fred Hutchinson Cancer Research Center.therapeutic programs. We expect our existing capital resources as of the date of this report to be sufficient to fund our planned operations for at least the next six to ten months. To fund our operations for at least the next 12 months under our current business plan, we estimate that we would need between $2 million and $5 millionremainder of additional capital.2014. If we are unable to raise this amount ofadditional capital when needed, however, we could be forced to curtail or cease operations. Our future capital uses and requirements depend on numerous forward-looking factors. These factors include the following:
· | the time and | |
· | the expense associated with building a network of sales representatives to market the ForeCYTE our planned therapeutic programs; and |
· | the degree and speed of patient and physician acceptance of our products and the degree to which third-party payors approve the |
Since inception (April 30, 2009) through September 30, 2013,March 31, 2014, we have generated $1,068,687$1,140,024 in revenue. We do not expect to generate significant revenue until we are ablereceive FDA clearance to manufacture and launchmarket the MASCT System more broadly.ForeCYTE Breast Aspirator. We expect our continuing operating losses to result in increases in cash used in operations over at least the next year. Although we expect our existing resources as of the date of this report, to be sufficient to fund our planned operations for at least the next six to ten months,through 2014, we may require additional funds earlier than we currently expect to successfully commercialize the ForeCYTE System.Breast Aspirator. Because of the numerous risks and uncertainties associated with the development and commercialization of the ForeCYTE TestBreast Aspirator and our services,other devices, tests and therapeutics in the pipeline, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated research and development activities and commercialization efforts.
Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.
If adequate funds are not available, we may be required to terminate, significantly modify or delay our development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.
Off-Balance Sheet Arrangements
We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.
Recent Accounting Pronouncements
The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.
Not applicable.
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2013.March 31, 2014. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2013,March 31, 2014, our principal executive officer and principal financial officer concluded that, as of such date, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended September 30, 2013March 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
On June 30, 2011, Robert Kelly, the Company’s former President, filed a counterclaim against the Company in an arbitration proceeding, alleging breach of contract in connection with the termination of a consulting agreement between Mr. Kelly (dba Pitslayer LLC) and the Company that was entered into in July 2010 in connection with his resignation from the Company as President and a director. The consulting agreement was terminated by the Company in September 2010. Mr. Kelly seeks $450,000 in compensatory damages, which is the amount he claims would have been earned had the consulting agreement been fulfilled to completion.
On December 11, 2012, Mr. Kelly filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the termination of Mr. Kelly’s consulting contract and the rescission of shares issued to him in July 2010 in connection with his resignation from the Company as President and a director. The specific amount of damages sought is to be proven at trial and is not specified. On July 8, 2013 the court granted the Company’s motion to compel arbitration of these claims and therefore this action was dismissed.
On February 26, 2013, Mr. Victor Cononi filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the rescission of shares issued to him in July 2010 in connection with Mr. Kelly’s resignation from the Company as President and a director. The specific amount of damages sought is to be proven at trial and is not specified. In August 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action was dismissed.
A hearing in the arbitration has been postponed pending certain procedures in the above Western Division action and may be delayed further to accommodate other third party civil and federal criminal proceedings alleging securities and wire fraud that have been brought against Mr. Kelly with respect to his prior employment and predating his service with the Company.
The Company is reasonably confident in its defenses to Mr. Kelly’s and Mr. Cononi’s claims. Consequently, no provision or liability has been recorded for these claims as of September 30, 2013.March 31, 2014. However, it is at least reasonably possible that the Company’s estimate of liability may change in the near term. Any payments by reason of an adverse determination in this matter will be charged to earnings in the period of determination.
On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.
On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel. The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation. No. 2:13-cv-01836-RSM. An amended complaint was filed on April 15, 2014.
We believe this complaint is without merit and plan to defend ourselves vigorously. Failure by us to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on our business, results of operations and financial condition. Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of September 30, 2013.March 31, 2014. The costs associated with defending and resolving the complaint and ultimate outcome cannot be predicted. These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of our business, will depend upon many unknown factors and management’s view of these may change in the future.
RISK FACTORS
A purchase of our shares of Common Stock is an investment in our securities and involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this report, before purchasing our securities. If any of the following risks actually occur, our business, financial condition and results of operations would likely suffer. In that case, the market price of the Common Stock could decline, and you may lose part or all of your investment in our company. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business and results of operations.
There has been no material changes to our Business
Anticipated liquidity issues in the ForeCYTE and ArgusCYTE tests, conducting research and development onnext four to twelve months.
For the FullCYTE and NextCYTE tests, securing distribution partners and beginning the commercialization of our products. We did not begin the national launch of the ForeCYTE test until January 2013quarter ended March 31, 2014, we generated no revenue and we subsequently recalledincurred a net loss of $2,411,531. Through March 31, 2014, we had an accumulated deficit of approximately $22.9 million. We expect that product in October 2013.our existing resources will be sufficient to fund our planned operations through 2014. We will require significant additional capital to achieve our business objectives, and the inability to obtain such financing on acceptable terms or at all could lead to closure of the business.
Failure to adequately and timely address the FDA’s warning letter received February 21, 2013, or other matters raised by the FDA, could adversely affect our business.
None
Not applicable.
Not applicable.
On May 12, 2014, Ben Chen, Sr. Vice President Global Regulatory Affairs and Quality Assurance, resigned from the Company. The March 27, 2013 Common Stock Purchase Agreement with Aspire Capital was terminated on November 8, 2013 and on that date we entered intoCompany is actively seeking a new stock purchase agreement with Aspire Capital Fund, LLC. The new stock purchase agreement provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire is committed to purchase up to an aggregate of $25 million of shares of our common stock over the 30 month term of the agreement. We cannot, however, sell any shares to Aspire under the new agreement unless and until a new registration statement is filed with and declared effective by the SEC. Information about our agreements with Aspire Capital is contained in Part I, Item 2, which is incorporated in this Part II, Item 5, by this reference.
(a) | Exhibits |
10.2# |
31.1 | Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of Steven C. Quay |
31.2 | Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of Kyle Guse |
32.1 | Certification pursuant to 18 U.S.C. Section 1350 of Steven C. Quay |
32.2 | Certification pursuant to 18 U.S.C. Section 1350 of Kyle Guse |
101* | Interactive Data Files pursuant to Rule 405 of Regulation S-T |
# Indicates management contract or compensatory plan, contract or arrangement.
* Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act, are deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under these sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 12, 2013
/s/ Steven C. Quay | |
President and Chief Executive Officer | |
(On behalf of the Registrant) |
/s/ Kyle Guse | |
Kyle Guse | |
Chief Financial Officer, General Counsel and Secretary | |
(As Principal Financial and Accounting Officer) |
37 |